Resistance mutation info of drug
| Drug General Information | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Drug ID | D0O5NK | ||||||||||
| Drug Name | Oseltamivir | ||||||||||
| Synonyms | Tamiflu (*Phosphate salt 1:1*); Agucort; Oseltamivirum; Tamvir; GS 4104; GS4104; Agucort (TN); GS-4104; Oseltamivir (INN); Oseltamivir [INN:BAN]; Ro-640796; Tamiflu (TN); Tamiflu-Free; Ro-64-0796; OTV | ||||||||||
| Drug Type | Small molecular drug | ||||||||||
| Therapeutic Class | Antiviral Agents | ||||||||||
| Company | Hoffmann-La Roche pharmaceutical company | ||||||||||
| Structure |
|
||||||||||
| Drug Resistance Mutations | |||||||||||
| Target Name | Influenza Neuraminidase (NA) | Target Info | |||||||||
| Gene Name | NA | ||||||||||
| Uniprot ID | C3W5Y1_9INFA | ||||||||||
| Species | Influenza A viruses H1N1 | ||||||||||
| Reference Sequence |
MNPNQKIITIGSVCMTIGMANLILQIGNIISIWISHSIQLGNQNQIETCNQSVITYENNT WVNQTYVNISNTNFAAGQSVVSVKLAGNSSLCPVSGWAIYSKDNSVRIGSKGDVFVIREP FISCSPLECRTFFLTQGALLNDKHSNGTIKDRSPYRTLMSCPIGEVPSPYNSRFESVAWS ASACHDGINWLTIGISGPDNGAVAVLKYNGIITDTIKSWRNNILRTQESECACVNGSCFT VMTDGPSNGQASYKIFRIEKGKIVKSVEMNAPNYHYEECSCYPDSSEITCVCRDNWHGSN RPWVSFNQNLEYQIGYICSGIFGDNPRPNDKTGSCGPVSSNGANGVKGFSFKYGNGVWIG RTKSISSRNGFEMIWDPNGWTGTDNNFSIKQDIVGINEWSGYSGSFVQHPELTGLDCIRP CFWVELIRGRPKENTIWTSGSSISFCGVNSDTVGWSWPDGAELPFTIDK [Influenza A viruses H1N1] |
||||||||||
| Targeted Disease | Influenza infection | ||||||||||
| Drug Resistance Mutations |
|
||||||||||
|
|||||||||||
| Target Name | Influenza Proton channel protein (M2) | Target Info | |||||||||
| Gene Name | M2 | ||||||||||
| Uniprot ID | M2_I35A3 | ||||||||||
| Species | Influenza A viruses H1N1 | ||||||||||
| Reference Sequence |
MSLLTEVETPIRNEWGCRCNGSSDPLVIAASIIGILHLILWILDRLLFKCIYRRFKYGLK RGPSTEGVPESMREEYRKEQQSAVDADDGHFVNIEPE [Influenza A viruses H 1N1] |
||||||||||
| Targeted Disease | Influenza infection | ||||||||||
| Drug Resistance Mutations |
|
||||||||||
| References | |||||||||||
| REF 1 | Insights into susceptibility of antiviral drugs against the E119G mutant of 2009 influenza A (H1N1) neuraminidase by molecular dynamics simulations and free energy calculations. Antiviral Res. 2013 Nov;100(2):356-64. | ||||||||||
| REF 2 | Design and expeditious synthesis of organosilanes as potent antivirals targeting multidrug-resistant influenza A viruses. Eur J Med Chem. 2017 Jul 28;135:70-76. | ||||||||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.